Takeda Pharmaceutical (TAK) said Tuesday the European Commission approved Adcetris in combination with a chemotherapy regimen to treat patients with stage 2b, 3 and 4 Hodgkin lymphoma.
The Commission's approval follows a recommendation from the Committee for Medicinal Products for Human Use on April 25, according to a statement.
The approval is based on the phase 3 HD21 trial, which achieved its co-primary safety and efficacy endpoints, the company said.
It added that the development marks the second approval for the drug regimen for the treatment of Hodgkin lymphoma.
Price: 14.99, Change: -0.09, Percent Change: -0.60
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。